Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Fiche publication
Date publication
janvier 2017
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S
Lien Pubmed
Résumé
The best noninvasive method predicting clinical relapse remains undetermined in infliximab (IFX)-treated patients with Crohn's disease.
Mots clés
Adult, Azathioprine, administration & dosage, C-Reactive Protein, analysis, Crohn Disease, diagnosis, Feces, chemistry, Female, Gastrointestinal Agents, administration & dosage, Humans, Infliximab, administration & dosage, Leukocyte L1 Antigen Complex, analysis, Logistic Models, Maintenance Chemotherapy, methods, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Recurrence, Severity of Illness Index, Treatment Outcome
Référence
Inflamm. Bowel Dis.. 2017 01;23(1):126-132